Abstract:Abstract Background: CB-012 is an allogeneic anti-CLL-1 CAR-T cell therapy in development for evaluation in relapsed or refractory acute myeloid leukemia (r/r AML). CB-012 is engineered with a next-generation CRISPR genome-editing technology to leverage both checkpoint disruption and immune cloaking to enhance persistence of CAR-T cell antitumor activity. Methods: Caribou’s CRISPR hybrid RNA-DNA (chRDNA) guides in combination with Cas12a were used to make five edits in the manufacture of CB-012. A fully human anti-CLL-1 CAR transgene was site-specifically inserted into the TRAC gene, thereby eliminating TCR expression to prevent graft-versus-host disease. A B2M-HLA-E fusion transgene was inserted into the native B2M gene, preventing expression of all HLA class I antigens except HLA-E, to blunt both T and NK cell-mediated allograft rejection of the CAR-T cells. A knockout of the PDCD1 gene prevented PD-1 receptor expression and thus PD-L1 ligand binding, thereby prolonging antitumor activity. These multiplex genome-editing strategies were designed to enhance persistence of CB-012 antitumor activity and potentially achieve durable therapeutic responses. Results: CB-012 CAR-T cells express a potent, fully human anti-CLL-1 scFv CAR construct and demonstrate CLL-1-dependent cytotoxicity, proliferation, and cytokine secretion in vitro using AML cell line models. In AML xenografts, robust tumor control and prolongation of survival was observed following a single dose of CB-012. In serial rechallenge assays, CB-012 cells maintained increased cytolytic potential when repeatedly challenged with CLL-1-expressing tumor cells compared to similarly engineered CAR-T cells without a PD-1 knockout, demonstrating a functional benefit of PD-1 abrogation. This advantage was modelled in vivo, conferring superior prolongation of survival with CB-012 treatment compared to similarly engineered CAR-T cells without a PD-1 knockout. Additionally, CB-012 cells expressing the B2M-HLA-E fusion demonstrated resistance to NK cell-mediated cytotoxicity in vitro. Conclusions: CLL-1 is a compelling therapeutic target as it is highly expressed on AML tumor cells and leukemic stem cells, but not expressed on hematopoietic stem cells. It has also been established as a target in human proof-of-concept studies. CB-012 demonstrated potent and specific CLL-1-targeted cytolytic activity, and the genome-editing strategy employed to manufacture and armor CB-012 conferred a functional advantage in the context of the potentially immunosuppressive tumor microenvironment associated with r/r AML. Citation Format: Elizabeth Garner, Erin Kelly, Sai Namburi, Cian Colgan, Tristan Fowler, Devin Mutha, Art Aviles, Morena Stanaway, Raymond Guo, Zili An, Emilie Degagne, George Kwong, Leslie Edwards, Emma Jakes, McKay Shaw, Benjamin Schilling, Jeremy Huynh, Ricky Luu, Max Sidorov, Rhonda Mousali, Mikk Otsmaa, Justin Skoble, Steven Kanner. CB-012, an allogeneic anti-CLL-1 CAR-T cell therapy engineered with next-generation CRISPR technology to resist both the immunosuppressive tumor microenvironment and immune cell-mediated rejection, for patients with relapsed or refractory acute myeloid leukemia [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 3201.

Allogeneic chimeric antigen receptor-T cells with CRISPR-disrupted programmed death-1 checkpoint exhibit enhanced functional fitness

Engineered triple inhibitory receptor resistance improves anti-tumor CAR-T cell performance via CD56

CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells

Contextual reprogramming of CAR-T cells for treatment of HER2+ cancers

Abstract 3201: CB-012, an allogeneic anti-CLL-1 CAR-T cell therapy engineered with next-generation CRISPR technology to resist both the immunosuppressive tumor microenvironment and immune cell-mediated rejection, for patients with relapsed or refractory acute myeloid leukemia

Targeting and Cytotoxicity of Chimeric Antigen Receptor T Cells Grafted with PD1 Extramembrane Domain

Non-viral expression of chimeric antigen receptors with multiplex gene editing in primary T cells

Abstract 34: Improving CAR T cell efficacy in pancreatic cancer using an in vivo CRISPR Cas9 screen

Abstract PR-02: CRISPR/Cas9 Engineering of Next-Generation Armoured CAR T Cells

Disruption of PD-1 Enhanced the Anti-tumor Activity of Chimeric Antigen Receptor T Cells Against Hepatocellular Carcinoma.

PD-1 downregulation enhances CAR-T cell antitumor efficiency by preserving a cell memory phenotype and reducing exhaustion

Abstract 3999: Augmentation of antitumor effects by CAR-T cells secreting anti-PD-1 single-chain antibody fused with IL-21

PD-L1 chimeric costimulatory receptor improves the efficacy of CAR-T cells for PD-L1-positive solid tumors and reduces toxicity in vivo

CRISPR/Cas9-mediated PD-1 Disruption Enhances Human Mesothelin-Targeted CAR T Cell Effector Functions.

Abstract 52: CRISPR-mediated knock-out of A20 lowers the activation threshold and induces metabolic rewiring of CAR-T cells

Genome-wide CRISPRa screens nominate modulators of CAR T cell survival within distinct tumor cytokine milieus

Generation of Cancer-Specific Cytotoxic PD-1- T Cells Using Liposome-Encapsulated CRISPR/Cas System with Dendritic/Tumor Fusion Cells

CD5 deletion enhances the antitumor activity of adoptive T cell therapies

Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors

Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells

Engineered Cells for Costimulatory Enhancement Combined with IL-21 Enhance the Generation of PD-1-disrupted CTLs for Adoptive Immunotherapy.